FDA Drug · D-0908-2023

Fexofenadine Hydrochloride Tablets, 180 mg, packaged in a) 30-count cartons (NDC 0113-0847-39), and b) 45-count cartons (NDC 0113-0847-95), Distributed by: Perrigo, Allegan, MI 49010.

Class II · Terminated

Failed Impurities/Degradation Specifications

Affected lots / codes — check yours against thisLot #: a) 2DV1869, 2EV1613, 2EV1614, Exp. date 12/23; 2EV1820, 2FV1943, Exp. date 01/24; 2GV1893, Exp. date 04/24. Lot #: b) 2CR0653, 2DR0466, Exp. date 12/23, 2ER2087, Exp. date 01/24

Recalling firm: L. Perrigo Company, Allegan, MI
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 32,376 cartons
Distribution: Nationwide within the USA
Recall initiated: February 9, 2023
Classified: July 11, 2023
Terminated: September 11, 2023
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0908-2023%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →